NEUROMYELITIS OPTICA SPECTRUM DISORDER
Clinical trials for NEUROMYELITIS OPTICA SPECTRUM DISORDER explained in plain language.
Never miss a new study
Get alerted when new NEUROMYELITIS OPTICA SPECTRUM DISORDER trials appear
Sign up with your email to follow new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug hopes to stop relapses in kids with rare nerve disease
Disease control OngoingThis study tests ravulizumab, a drug that calms a part of the immune system, in 12 children with NMOSD – a rare disease where the immune system attacks the nerves in the eyes and spine. The goal is to see if the drug can reduce the number of relapses and prevent disability over a…
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER
Phase: PHASE2, PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New study tracks immune effects of NMOSD drug over years
Disease control OngoingThis study looks at the long-term safety of inebilizumab (UPLIZNA) in people with neuromyelitis optica spectrum disorder (NMOSD). Researchers will measure immune markers like immunoglobulins and B-cells in 32 participants during treatment and after stopping. The goal is to unders…
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER
Phase: PHASE4 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New drug aims to stop NMOSD attacks in its tracks
Disease control OngoingThis phase 3 trial tests a drug called MIL62 in 102 people with neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease that attacks the optic nerves and spinal cord. Participants receive MIL62 or a placebo by IV infusion over several months. The main goal is to…
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER
Phase: PHASE3 • Sponsor: Beijing Mabworks Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New device aims to help NMOSD patients walk better
Symptom relief ENROLLING_BY_INVITATIONThis study tests a device called MR-C-014 that uses sound to help people with neuromyelitis optica spectrum disorder (NMOSD) who have trouble walking. Thirty adults will use the device for 30 minutes, three times a week for 8 weeks. The main goals are to see if people find it acc…
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER
Phase: NA • Sponsor: MedRhythms, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
800 NMOSD patients join landmark registry to unlock disease secrets
Knowledge-focused ENROLLING_BY_INVITATIONThis observational study will follow about 800 adults with neuromyelitis optica spectrum disorder (NMOSD) across North America. Researchers will collect data on how the disease presents, progresses, and is managed in real-world settings. No experimental treatments are given; the …
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER
Sponsor: CorEvitas • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Scientists launch major effort to unravel mysteries of rare brain and spinal cord diseases
Knowledge-focused OngoingThis study follows 150 people with rare neuroimmunologic disorders like neuromyelitis optica and transverse myelitis. Researchers collect medical data and blood samples over time to learn what causes inflammation and why some patients respond to treatments while others do not. Th…
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER
Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC